Recent developments include capital raises, strategic acquisitions, program milestones, and collaborations advancing Pluri's cell-based product initiatives.

• Pluri priced a $3.3 million registered direct offering and concurrent private placement in August 2026 to raise capital [N1].
• The company successfully completed the first phase of its Resbiomed program for placenta-derived collagen-rich biomaterials in January 2026 [N2].
• Alliance Global Partners initiated coverage of Pluri with a buy recommendation in June 2025 [N3].
• Pluri acquired 71% of Kokomodo Ltd. to advance climate-resilient cultivated cacao production in April 2025 [N4].
• Ever After Foods and Bühler announced a collaboration to advance scalable cultivated meat production in February 2025 [N5].
• Pluri announced a $6.5 million private placement and strategic acquisition of 71% stake in Kokomodo Ltd. in January 2025 [N6][N7].
• The company congratulated Mesoblast's CEO on FDA approval of an MSC-based therapy in December 2024 [N8].
• Pluri is evaluating mass production readiness of its PLX-R18 product for acute radiation syndrome amid nuclear threats as of November 2024 [N1].
• Pluri entered a memorandum of understanding with BrainStorm to support the NurOwn trial in November 2024 [N1].

Pluri's diversified approach across regenerative medicine, FoodTech, and aesthetics, combined with strategic acquisitions and partnerships, positions it to leverage emerging cell-based technologies in multiple markets. Successful advancement of its Resbiomed program and readiness for mass production of PLX-R18 could enhance its product pipeline. The acquisition of Kokomodo Ltd. expands its footprint into climate-resilient cultivated cacao, potentially opening new revenue streams. Capital raises and collaborations support ongoing development and commercialization efforts, which could improve operational scale and market presence.

Pluri faces significant challenges including recurring operating losses, liquidity constraints, and substantial doubt about its ability to continue as a going concern. The company depends on raising additional capital, which may be costly or dilutive. Regulatory approval processes are complex and uncertain, with risks of delays or failures. Manufacturing and commercialization risks, competition from better-funded entities, and geopolitical risks related to its Israeli operations add to the uncertainty. Failure to achieve market acceptance or regulatory clearance for its products could severely limit revenue generation and business viability.

Pluri's moat is based on its proprietary cell-based technology platform applied across diverse sectors including regenerative medicine, FoodTech, and aesthetics. Strategic acquisitions, such as the majority stake in Kokomodo Ltd., and collaborations with industry partners enhance its technological capabilities and market reach. However, the company operates in highly competitive and regulated industries with significant technological and regulatory barriers, which may provide some protection but also pose challenges to commercialization and scalability. The limited operating history and ongoing need for capital to fund research and development and commercialization efforts constrain the moat's strength at this stage.

• Liquidity and Going Concern Risk: Pluri has recurring operating losses and negative cash flow, with limited cash and current assets relative to liabilities, raising substantial doubt about its ability to continue as a going concern without additional financing [S1].
• Capital Raising Risk: The company needs to raise significant additional capital to fund operations and development. Capital raising may be costly, dilutive, or difficult to obtain, impacting shareholder value and operational continuity [S1].
• Regulatory Approval Risk: Pluri's products require regulatory approvals from agencies such as the FDA and EMA. Delays, failures, or additional regulatory burdens could adversely affect commercialization and revenues [S1].
• Manufacturing and Operational Risks: There are inherent risks in manufacturing cell-based products to meet high regulatory standards. Failures could materially impact results and business value [S1].
• Competitive and Intellectual Property Risks: The company may face claims from larger competitors enforcing IP rights or seeking to invalidate its IP. Competition from better-funded entities poses risks to market share and profitability [S1].
• Geopolitical and Currency Risks: Operations in Israel expose Pluri to geopolitical risks and currency exchange fluctuations, which could materially affect financial condition and results [S1].

• Pluri Inc. is engaged in developing cell-based products primarily in regenerative medicine, FoodTech, aesthetics, wellness, longevity, and CDMO services.
• The company has a limited operating history and has not generated significant or consistent revenues to date.
• For fiscal year ended June 30, 2026, Pluri reported revenues of $1.016 million and a net loss of $23.821 million, with basic and diluted EPS of -2.44 USD per share.
• As of June 30, 2026, Pluri had cash and cash equivalents of $3.529 million and current assets of $8.73 million against current liabilities of $32.719 million, resulting in a current ratio of 0.27 and a cash ratio of 0.37, indicating liquidity constraints.
• The company has recurring operating losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern as noted by its independent auditor.
• Pluri has a loan from the European Investment Bank (EIB) of approximately €20 million received in 2021, due June 1, 2026, with accrued interest and royalty payment obligations.
• The company is actively engaged in raising capital, including a $3.3 million registered direct offering and concurrent private placement in August 2026.
• Pluri acquired a 71% stake in Kokomodo Ltd. to advance climate-resilient cultivated cacao production, supported by a $6.5 million private placement to fund this acquisition.
• The company collaborates with partners such as Ever After Foods and Bühler to advance scalable cultivated meat production.
• Pluri completed the first phase of its Resbiomed program for placenta-derived collagen-rich biomaterials in January 2026.
• The company is evaluating mass production readiness of its PLX-R18 product for acute radiation syndrome amid nuclear threats.
• Pluri entered a memorandum of understanding with BrainStorm to support the NurOwn trial.
• The company faces risks including the need for additional capital, regulatory approval challenges, manufacturing risks, competition, and geopolitical risks related to its operations in Israel.
• Pluri's business model includes licensing, development, and commercialization of cell-based products and services, with ongoing research and development expenses exceeding $11 million net in recent periods.
• The company has experienced fluctuations in revenues and operating losses, with operating loss of $19.392 million for the nine months ended March 31, 2026.
• Pluri's shares outstanding increased from approximately 7.9 million to over 10.4 million shares between June 2025 and March 2026, reflecting capital raises and share-based compensation.
• The company is listed on The Nasdaq Capital Market under ticker PLUR.